{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:54:26Z","timestamp":1783997666425,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Hebei Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["H2019106063"],"award-info":[{"award-number":["H2019106063"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the S&T Program of Hebei","award":["19277701D"],"award-info":[{"award-number":["19277701D"]}]},{"name":"Hebei Province Innovation capability Improvement plan project","award":["20577715D"],"award-info":[{"award-number":["20577715D"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40120-023-00442-3","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:27:49Z","timestamp":1676392069000},"page":"559-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Identification of Potential Serum Protein Biomarkers in Thymoma with Myasthenia Gravis After Docetaxel Treatment"],"prefix":"10.1007","volume":"12","author":[{"given":"Hongxia","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9218-3219","authenticated-orcid":false,"given":"Guoyan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"issue":"1","key":"442_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.","journal-title":"Nat Rev Dis Primers"},{"key":"442_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10:46.","journal-title":"BMC Neurol"},{"issue":"2","key":"442_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1212\/WNL.0b013e3181ad53c2","volume":"73","author":"AT Heldal","year":"2009","unstructured":"Heldal AT, Owe JF, Gilhus NE, Romi F. Seropositive myasthenia gravis: a nationwide epidemiologic study. Neurology. 2009;73(2):150\u20131.","journal-title":"Neurology"},{"key":"442_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2020.100063","volume":"5","author":"J Chen","year":"2020","unstructured":"Chen J, Tian DC, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study. Lancet Reg Health West Pac. 2020;5:100063.","journal-title":"Lancet Reg Health West Pac"},{"issue":"10","key":"442_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023\u201336.","journal-title":"Lancet Neurol"},{"issue":"1","key":"442_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/nyas.13592","volume":"1413","author":"A Vincent","year":"2018","unstructured":"Vincent A, Huda S, Cao M, et al. Serological and experimental studies in different forms of myasthenia gravis. Ann N Y Acad Sci. 2018;1413(1):143\u201353.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"442_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.25973","volume":"57","author":"JS Yi","year":"2018","unstructured":"Yi JS, Guptill JT, Stathopoulos P, Nowak RJ, O\u2019Connor KC. B cells in the pathophysiology of myasthenia gravis. Muscle Nerve. 2018;57(2):172\u201384.","journal-title":"Muscle Nerve"},{"issue":"3","key":"442_CR8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/cei.13546","volume":"203","author":"A Uzawa","year":"2021","unstructured":"Uzawa A, Kuwabara S, Suzuki S, et al. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol. 2021;203(3):366\u201374.","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"442_CR9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00401-021-02299-y","volume":"141","author":"F Ingelfinger","year":"2021","unstructured":"Ingelfinger F, Krishnarajah S, Kramer M, et al. Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature. Acta Neuropathol. 2021;141(6):901\u201315.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"442_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11748-007-0185-8","volume":"56","author":"M Okumura","year":"2008","unstructured":"Okumura M, Fujii Y, Shiono H, et al. Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis. Gen Thorac Cardiovasc Surg. 2008;56(4):143\u201350.","journal-title":"Gen Thorac Cardiovasc Surg"},{"issue":"6","key":"442_CR11","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1111\/ene.14820","volume":"28","author":"R \u00c1lvarez-Velasco","year":"2021","unstructured":"\u00c1lvarez-Velasco R, Guti\u00e9rrez-Guti\u00e9rrez G, Trujillo JC, et al. Clinical characteristics and outcomes of thymoma-associated myasthenia gravis. Eur J Neurol. 2021;28(6):2083\u201391.","journal-title":"Eur J Neurol"},{"issue":"5","key":"442_CR12","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/ejcts\/ezz334","volume":"57","author":"KJ Na","year":"2020","unstructured":"Na KJ, Hyun K, Kang CH, et al. Predictors of post-thymectomy long-term neurological remission in thymomatous myasthenia gravis: an analysis from a multi-institutional database. Eur J Cardiothorac Surg. 2020;57(5):867\u201373.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"2","key":"442_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1053\/j.semtcvs.2016.04.002","volume":"28","author":"AJ Kaufman","year":"2016","unstructured":"Kaufman AJ, Palatt J, Sivak M, et al. Thymectomy for myasthenia gravis: complete stable remission and associated prognostic factors in over 1000 cases. Semin Thorac Cardiovasc Surg. 2016;28(2):561\u20138.","journal-title":"Semin Thorac Cardiovasc Surg"},{"issue":"7","key":"442_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/JTO.0b013e318292c41e","volume":"8","author":"S Park","year":"2013","unstructured":"Park S, Ahn MJ, Ahn JS, et al. A prospective phase II trial of induction chemotherapy with docetaxel\/cisplatin for Masaoka stage III\/IV thymic epithelial tumors. J Thorac Oncol. 2013;8(7):959\u201366.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"442_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1620\/tjem.241.281","volume":"241","author":"G Qi","year":"2017","unstructured":"Qi G, Liu P, Dong H, Gu S, Yang H, Xue Y. Therapeutic potential of docetaxel plus cisplatin chemotherapy for myasthenia gravis patients with metastatic thymoma. Tohoku J Exp Med. 2017;241(4):281\u20136.","journal-title":"Tohoku J Exp Med"},{"key":"442_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1515\/med-2017-0058","volume":"12","author":"G Qi","year":"2017","unstructured":"Qi G, Xue Y, Li Y, Yang H, Zhang X. Docetaxel\/cisplatin therapy in myasthenia gravis with hypertension\/diabetes. Open Med (Wars). 2017;12:403\u20138.","journal-title":"Open Med (Wars)"},{"issue":"8","key":"442_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11306-019-1571-9","volume":"15","author":"D Blackmore","year":"2019","unstructured":"Blackmore D, Siddiqi Z, Li L, Wang N, Maksymowych W. Beyond the antibodies: serum metabolomic profiling of myasthenia gravis. Metabolomics. 2019;15(8):109.","journal-title":"Metabolomics"},{"issue":"1","key":"442_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12883-020-01885-z","volume":"20","author":"QX Zhang","year":"2020","unstructured":"Zhang QX, Li Y, Jiang SM, et al. Increased serum IL-36\u03b3 levels are associated with disease severity in myasthenia gravis patients. BMC Neurol. 2020;20(1):307.","journal-title":"BMC Neurol"},{"key":"442_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577634","volume":"358","author":"A Uzawa","year":"2021","unstructured":"Uzawa A, Akamine H, Kojima Y, et al. High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. J Neuroimmunol. 2021;358: 577634.","journal-title":"J Neuroimmunol"},{"issue":"4","key":"442_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"1","key":"442_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16\u201323.","journal-title":"Neurology"},{"issue":"D1","key":"442_CR22","doi-asserted-by":"publisher","first-page":"D330","DOI":"10.1093\/nar\/gky1055","volume":"47","author":"The Gene Ontology Consortium","year":"2019","unstructured":"The Gene Ontology Consortium. The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res. 2019;47(D1):D330\u20138.","journal-title":"Nucleic Acids Res"},{"key":"442_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/1471-2105-7-191","volume":"7","author":"J Ernst","year":"2006","unstructured":"Ernst J, Bar-Joseph Z. STEM: a tool for the analysis of short time series gene expression data. BMC Bioinform. 2006;7:191.","journal-title":"BMC Bioinform"},{"key":"442_CR24","doi-asserted-by":"publisher","first-page":"bav028","DOI":"10.1093\/database\/bav028","volume":"2015","author":"J Pi\u00f1ero","year":"2015","unstructured":"Pi\u00f1ero J, Queralt-Rosinach N, Bravo \u00c0, et al. DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. Database (Oxford). 2015;2015:bav028.","journal-title":"Database (Oxford)"},{"issue":"D1","key":"442_CR25","doi-asserted-by":"publisher","first-page":"D833","DOI":"10.1093\/nar\/gkw943","volume":"45","author":"J Pi\u00f1ero","year":"2017","unstructured":"Pi\u00f1ero J, Bravo \u00c0, Queralt-Rosinach N, et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res. 2017;45(D1):D833\u20139.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"442_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/17425247.2019.1583644","volume":"16","author":"E Zhang","year":"2019","unstructured":"Zhang E, Xing R, Liu S, Li P. Current advances in development of new docetaxel formulations. Expert Opin Drug Deliv. 2019;16(3):301\u201312.","journal-title":"Expert Opin Drug Deliv"},{"issue":"6","key":"442_CR27","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/cmdc.201200052","volume":"7","author":"P Zhao","year":"2012","unstructured":"Zhao P, Astruc D. Docetaxel nanotechnology in anticancer therapy. ChemMedChem. 2012;7(6):952\u201372.","journal-title":"ChemMedChem"},{"issue":"11","key":"442_CR28","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1158\/1078-0432.CCR-07-4025","volume":"14","author":"CT Garnett","year":"2008","unstructured":"Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res. 2008;14(11):3536\u201344.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"442_CR29","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/annonc\/mdv072","volume":"26","author":"GR Blumenschein Jr","year":"2015","unstructured":"Blumenschein GR Jr, Smit EF, Planchard D, et al. A randomized phase II study of the MEK1\/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2015;26(5):894\u2013901.","journal-title":"Ann Oncol"},{"issue":"14","key":"442_CR30","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The frequency of Ras mutations in cancer. Cancer Res. 2020;80(14):2969\u201374.","journal-title":"Cancer Res"},{"issue":"3","key":"442_CR31","doi-asserted-by":"publisher","first-page":"577","DOI":"10.18632\/oncotarget.1775","volume":"5","author":"E Schmukler","year":"2014","unstructured":"Schmukler E, Kloog Y, Pinkas-Kramarski R. Ras and autophagy in cancer development and therapy. Oncotarget. 2014;5(3):577\u201386.","journal-title":"Oncotarget"},{"issue":"1","key":"442_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-022-01629-2","volume":"21","author":"C Zhu","year":"2022","unstructured":"Zhu C, Guan X, Zhang X, et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022;21(1):159.","journal-title":"Mol Cancer"},{"issue":"4","key":"442_CR33","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.4049\/jimmunol.1502112","volume":"196","author":"Y Chen","year":"2016","unstructured":"Chen Y, Zheng Y, You X, et al. Kras is critical for B cell lymphopoiesis. J Immunol. 2016;196(4):1678\u201385.","journal-title":"J Immunol"},{"issue":"4","key":"442_CR34","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/2326-6066.CIR-15-0241","volume":"4","author":"S Zdanov","year":"2016","unstructured":"Zdanov S, Mandapathil M, Abu Eid R, et al. Mutant KRAS conversion of conventional T cells into regulatory T cells. Cancer Immunol Res. 2016;4(4):354\u201365.","journal-title":"Cancer Immunol Res"},{"issue":"25","key":"442_CR35","doi-asserted-by":"publisher","first-page":"E1629","DOI":"10.1073\/pnas.1117640109","volume":"109","author":"K Singh","year":"2012","unstructured":"Singh K, Deshpande P, Li G, et al. K-RAS GTPase- and B-RAF kinase-mediated T-cell tolerance defects in rheumatoid arthritis. Proc Natl Acad Sci USA. 2012;109(25):E1629\u201337.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"442_CR36","doi-asserted-by":"publisher","first-page":"e103872","DOI":"10.1371\/journal.pone.0103872","volume":"9","author":"J Burkhardt","year":"2014","unstructured":"Burkhardt J, Blume M, Petit-Teixeira E, et al. Cellular adhesion gene SELP is associated with rheumatoid arthritis and displays differential allelic expression. PLoS ONE. 2014;9(8):e103872.","journal-title":"PLoS ONE"},{"issue":"2","key":"442_CR37","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1365-2249.1995.tb03785.x","volume":"102","author":"M Marazuela","year":"1995","unstructured":"Marazuela M, S\u00e1nchez-Madrid F, Acevedo A, Larra\u00f1aga E, de Land\u00e1zuri MO. Expression of vascular adhesion molecules on human endothelia in autoimmune thyroid disorders. Clin Exp Immunol. 1995;102(2):328\u201334.","journal-title":"Clin Exp Immunol"},{"key":"442_CR38","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.12659\/MSM.895144","volume":"21","author":"YH Hu","year":"2015","unstructured":"Hu YH, Zhou PF, Long GF, et al. Elevated plasma P-selectin autoantibodies in primary Sj\u00f6gren syndrome patients with thrombocytopenia. Med Sci Monit. 2015;21:3690\u20135.","journal-title":"Med Sci Monit"},{"issue":"3","key":"442_CR39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1084\/jem.20020691","volume":"198","author":"W Haddad","year":"2003","unstructured":"Haddad W, Cooper CJ, Zhang Z, et al. P-selectin and P-selectin glycoprotein ligand 1 are major determinants for Th1 cell recruitment to nonlymphoid effector sites in the intestinal lamina propria. J Exp Med. 2003;198(3):369\u201377.","journal-title":"J Exp Med"},{"issue":"8","key":"442_CR40","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.4049\/jimmunol.169.8.4307","volume":"169","author":"T Hirata","year":"2002","unstructured":"Hirata T, Furie BC, Furie B. P-, E-, and L-selectin mediate migration of activated CD8+ T lymphocytes into inflamed skin. J Immunol. 2002;169(8):4307\u201313.","journal-title":"J Immunol"},{"issue":"600","key":"442_CR41","doi-asserted-by":"publisher","first-page":"eabi4994","DOI":"10.1126\/scitranslmed.abi4994","volume":"13","author":"M Scherlinger","year":"2021","unstructured":"Scherlinger M, Guillotin V, Douchet I, et al. Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis. Sci Transl Med. 2021;13(600):eabi4994.","journal-title":"Sci Transl Med"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00442-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00442-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00442-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T12:40:26Z","timestamp":1679920826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00442-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["442"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00442-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"assertion":[{"value":"2 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}